Benzinga | Sep 15, 2021 05:23PM EDT

Isoray 8-K Shows Co.'s Isoray Medical Unit Entered Consignment Deal With MedikorPharma-Ural For Supply Of Ceisum-131

On September 9, 2021, Isoray Medical, Inc. ("Medical"), a wholly owned subsidiary of Isoray, Inc., entered into a Consignment Agreement (the "Agreement") with MedikorPharma-Ural LLC, a company incorporated in accordance with the laws of Russia ("Medikor").



Medical's source of supply of Cesium-131 is produced using two Russian nuclear reactors which supply the neutron irradiation needed for Cesium-131 production. One of the Russian nuclear reactors will be working at a reduced capacity and be shut down later in calendar year 2021. As a result of the upcoming shutdown, only one of Medical's historic suppliers of Cesium-131 will be available during these periods.



To help mitigate this situation, pursuant to the Agreement, Medical will purchase 6000 mg of enriched barium carbonate for $720,000, which is needed for the manufacture of Cesium-131, and consign this inventory to Medikor. It is expected that beginning in October 2021, Medikor will use the barium carbonate consigned by Medical and contract with a third-party manufacturer to produce Cesium-131. Pursuant to the Agreement, Medikor will pay Medical varying US dollar amounts per curie of Cesium-131 Medical purchases. The amount varies based on how many curies of Cesium-131 Medical purchases. It is further expected that a separate third-party contractor will receive the Cesium-131 produced by the third-party manufacturer and will sell the Cesium-131 exclusively to Medical. This arrangement would have the effect of minimizing the impact on Medical of the temporary shutdown of one of the nuclear reactors that serves as its source of Cesium-131 from Russia. Medical anticipates obtaining enough Cesium-131 under this arrangement to obtain over 5,000 curies of Cesium-131 through the end of the term, December 31, 2030, but there is no assurance as to whether the Agreement will be terminated before this full amount is obtained and other supply sources are used, nor is there assurance that the agreements with the third-parties will be executed.



The foregoing summary of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement. A copy of the Agreement is attached hereto as Exhibit 10.1 and is incorporated herein by reference.